Outlook Wealth Advisors LLC Buys 15,088 Shares of Invesco Biotechnology & Genome ETF $PBE

Outlook Wealth Advisors LLC purchased a new position in shares of Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 15,088 shares of the company’s stock, valued at approximately $1,468,000.

A number of other hedge funds also recently bought and sold shares of the stock. Royal Bank of Canada grew its position in shares of Invesco Biotechnology & Genome ETF by 25.9% during the first quarter. Royal Bank of Canada now owns 59,329 shares of the company’s stock worth $4,698,000 after buying an additional 12,215 shares in the last quarter. Investment House LLC acquired a new stake in Invesco Biotechnology & Genome ETF in the third quarter valued at approximately $582,000. Dynamic Advisor Solutions LLC acquired a new stake in Invesco Biotechnology & Genome ETF in the second quarter valued at approximately $484,000. Newman Dignan & Sheerar Inc. purchased a new position in Invesco Biotechnology & Genome ETF in the third quarter worth approximately $912,000. Finally, YHB Investment Advisors Inc. purchased a new position in Invesco Biotechnology & Genome ETF in the third quarter worth approximately $2,169,000.

Invesco Biotechnology & Genome ETF Stock Down 0.9%

NYSEARCA PBE opened at $102.50 on Friday. Invesco Biotechnology & Genome ETF has a 52 week low of $73.16 and a 52 week high of $104.24. The stock has a market capitalization of $445.88 million, a PE ratio of 20.44 and a beta of 0.70. The firm has a 50 day moving average of $96.99 and a two-hundred day moving average of $87.26.

About Invesco Biotechnology & Genome ETF

PowerShares Dynamic Biotechnology & Genome Portfolio (the Fund) is based on the Dynamic Biotechnology & Genome Intellidex Index (the Index). The Fund seeks investment results that correspond generally to the price and yield of the Index. The Index consists of stocks of 30 the United States biotechnology and genome companies. The Fund will normally invest at least 90% of its total assets in common stocks that consists of the Index. The Index is designed to provide capital appreciation by evaluating companies based on a variety of investment merit criteria, including fundamental growth, stock valuation, investment timeliness and risk factors.